Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NYSEAMERICAN:PHGE

BiomX Q4 2025 Earnings Results & Report

BiomX logo
$1.85 0.00 (0.00%)
As of 09/10/2026

BiomX reported Q4 2025 earnings on February 19, 2026. The company reported EPS of $69.90.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

BiomX EPS Results

Actual EPS
$69.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 4 quarters

BiomX Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

BiomX's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

BiomX's Q4 2025 Annual reportAnnual report
(10-K)

BiomX Q4 2025 Earnings FAQ

BiomX (NYSEAMERICAN:PHGE) reported earnings of $69.90 per share for Q4 2025. The report was announced on Thursday, February 19, 2026.

BiomX's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for BiomX on the company's earnings history page.

BiomX Earnings Headlines

Tessera Defense and Homeland Security CEO Issues Letter to Shareholders
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362229/0/en/tessera-defense-and-homeland-security-ceo-issues-letter-to-shareholders.html
Tessera Begins Trading Under HLSQ as Demand Grows for Connected Physical Security
September 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/tessera-begins-trading-under-hlsq-123000335.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 11 at 1:00 AM  |  Base Camp Trading (Ad)
BiomX Announces Reverse Stock Split and Rebranding Plan
September 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biomx-announces-reverse-stock-split-and-rebranding-plan?utm_source=marketbeat.com&utm_medium=referral
BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356598/0/en/biomx-zorronet-launches-no-code-control-over-ai-powered-autonomous-response-workflows.html
BiomX To Rebrand As Tessera Defense; Adopts HLSQ Ticker;Stock Up
September 1, 2026  |  rttnews.comhttps://www.rttnews.com/3687586/biomx-to-rebrand-as-tessera-defense-adopts-hlsq-ticker-stock-up.aspx
See More BiomX Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BiomX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BiomX and other key companies, straight to your email.

About BiomX

BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies. Its approach uses naturally occurring viruses, known as phages, to selectively identify and destroy harmful bacteria while seeking to preserve beneficial microorganisms in the microbiome.

The company’s lead program, BX004, is an inhaled phage therapy designed to target Pseudomonas aeruginosa, a bacterium associated with chronic lung infections in people with cystic fibrosis. BiomX has also developed additional phage-based programs aimed at bacterial infections and microbiome-related diseases, including gastrointestinal conditions. The company’s therapies are investigational and remain subject to clinical testing and regulatory review.

BiomX was founded in Israel and has advanced its development programs through clinical studies conducted in the United States and other locations. The company became publicly traded following a business combination with Chardan Healthcare Acquisition Corp. in 2019. BiomX’s operations are centered on research, clinical development and potential commercialization of precision antibacterial therapies.

View BiomX Profile
Earnings Tools